DDInter228 DDInter1658
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodg
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Brentuximab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pitavastatin
Brentuximab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis A Vaccine
Brentuximab vedotin {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Brentuximab vedotin {u} may lead to a major life threatening interaction when taken with {v} Samarium (153Sm) lexidronam
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Brentuximab vedotin may lead to a major life threatening interaction when taken with Teriflunomide
Brentuximab vedotin may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam